Opportunity Information: Apply for PA 16 030
Apply for PA 16 030
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.213, 93.361,.
- This funding opportunity was created on Nov 03, 2015 and posted on Nov 03, 2015.
- Applicants must submit their applications by Jan 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R01) is a discretionary research grant opportunity from the U.S. Department of Health and Human Services, National Institutes of Health (HHS-NIH). Issued as Funding Opportunity Announcement PA-16-030 and posted on November 3, 2015, it uses the NIH R01 mechanism, which is the standard award type for substantial, hypothesis-driven research projects. The core aim is to support studies that discover and validate biomarkers using metabolomics, specifically to improve how symptoms are understood, measured, and ultimately managed in clinical and health-related contexts. In practical terms, the program is looking for research that uses metabolomics (the large-scale measurement of small molecules and metabolic products in biological samples) to link biological pathways to patient symptoms, strengthen symptom assessment with objective indicators, and help guide better interventions or monitoring strategies.
The scientific focus is symptom science, meaning the work should center on symptoms as primary outcomes or key clinical problems rather than only on disease endpoints. The expectation is that metabolomics will be used as the primary discovery engine for biomarker identification, whether through untargeted profiling to find novel metabolic signatures or targeted assays to quantify specific metabolites connected to symptom presence, severity, trajectory, or treatment response. Biomarkers in this context can include metabolite patterns or panels that correlate with symptom clusters, differentiate subtypes of symptom experiences, predict who is likely to develop severe or persistent symptoms, or track symptom changes over time. The overall intent is to move beyond subjective reporting alone by adding biological measures that can improve precision in symptom assessment and inform individualized management.
Eligibility is broad and reflects NIH norms for R01 programs. Applicants may include public entities such as state, county, city or township governments, special district governments, and independent school districts, as well as public and state-controlled institutions of higher education. Eligible applicants also include federally recognized Native American tribal governments, other tribal organizations, public housing authorities/Indian housing authorities, and a wide range of private organizations. This includes private institutions of higher education, nonprofits with or without 501(c)(3) status (as long as they are not institutions of higher education in those categories), for-profit organizations that are not small businesses, and small businesses. The announcement also notes an "Others" category with additional eligibility details referenced in the full text, which is typical language for NIH opportunities that may permit additional applicant types under certain circumstances.
The opportunity is categorized under Education and Health in the funding activity area, and it is associated with CFDA numbers 93.213 and 93.361, which correspond to NIH program listings tied to the institutes and centers involved. The listed application due date for the referenced cycle is January 7, 2019 (both original and current closing dates match), indicating the specific closing window captured in the source data. Some administrative fields such as award ceiling and expected awards are not specified in the provided information, which often means applicants should rely on standard NIH R01 budgeting guidance and the details in the full announcement or institute-specific policies to estimate typical award sizes, durations, and paylines.
In summary, this FOA is designed for research teams that can combine symptom-focused clinical or population research with strong metabolomics capabilities to discover meaningful, reproducible biomarkers. The larger goal is to make symptom science more biologically grounded and clinically actionable by identifying metabolic signals that clarify mechanisms, improve measurement, and support better symptom management strategies.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The funding opportunity is titled "Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R01)."
Which agency is offering this grant?
This is a discretionary research grant opportunity from the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH).
What is the Funding Opportunity Announcement (FOA) number?
The FOA is PA-16-030.
When was this FOA posted?
The opportunity was posted on November 3, 2015.
What grant mechanism does this opportunity use?
This opportunity uses the NIH R01 mechanism, which is the standard NIH award type for substantial, hypothesis-driven research projects.
What is the main goal of this FOA?
The core aim is to support studies that discover and validate biomarkers using metabolomics in order to improve how symptoms are understood, measured, and ultimately managed in clinical and health-related contexts.
What does "symptom science" mean in this FOA?
Symptom science, in this context, means the research should center on symptoms as primary outcomes or key clinical problems, rather than focusing only on disease endpoints.
How is metabolomics expected to be used in the research?
Metabolomics is expected to be the primary discovery engine for identifying biomarkers. This may include untargeted profiling to find novel metabolic signatures or targeted assays to quantify specific metabolites related to symptoms.
What kinds of biomarkers are relevant under this FOA?
Biomarkers may include metabolite patterns or panels that correlate with symptom clusters, differentiate subtypes of symptom experiences, predict who may develop severe or persistent symptoms, or track symptom changes over time.
What practical outcomes is the program trying to achieve?
The program is looking for research that links biological pathways to patient symptoms, strengthens symptom assessment using objective indicators, and helps guide better interventions or monitoring strategies.
Does this FOA emphasize objective measures alongside patient-reported symptoms?
Yes. A stated intent is to move beyond subjective reporting alone by adding biological measures that can improve precision in symptom assessment and inform individualized management.
What types of studies might fit this FOA based on the description provided?
Studies that use metabolomics to discover and validate biomarkers tied to symptom presence, severity, trajectory, or treatment response, with symptoms treated as central outcomes, align with the described focus.
Who is eligible to apply?
Eligibility is broad and follows NIH norms for R01 programs. Eligible applicants include a wide range of public entities and private organizations, including higher education institutions, nonprofits, for-profits, small businesses, and certain tribal and housing authorities.
Are state or local governments eligible to apply?
Yes. Eligible public entities include state, county, city or township governments, special district governments, and independent school districts.
Are institutions of higher education eligible?
Yes. Public and state-controlled institutions of higher education, as well as private institutions of higher education, are listed as eligible applicants.
Are tribal organizations eligible?
Yes. Federally recognized Native American tribal governments and other tribal organizations are included in the eligibility list.
Are nonprofits eligible?
Yes. Nonprofits with or without 501(c)(3) status are listed as eligible, with the description noting category distinctions related to institutions of higher education.
Are for-profit organizations eligible?
Yes. For-profit organizations that are not small businesses are listed as eligible, and small businesses are also listed as eligible.
What does the "Others" eligibility category mean?
The announcement references an "Others" category with additional eligibility details that are typically described in the full FOA text, which may permit additional applicant types under certain circumstances.
What is the funding activity area for this opportunity?
The opportunity is categorized under Education and Health in the funding activity area.
What CFDA numbers are associated with this opportunity?
The associated CFDA numbers are 93.213 and 93.361.
What is the application due date listed in the provided information?
The listed application due date for the referenced cycle is January 7, 2019, and the original and current closing dates match in the provided data.
Are award amounts (award ceiling) provided?
No. The provided information states that some administrative fields, such as award ceiling, are not specified.
Does the provided information specify the number of expected awards?
No. Expected awards are not specified in the provided information.
How should applicants think about budgeting if award details are not specified here?
The provided information suggests relying on standard NIH R01 budgeting guidance and the details in the full announcement or institute-specific policies to understand typical award sizes, durations, and related expectations.
What capabilities would a strong applicant team likely need?
Based on the summary, the FOA is designed for research teams that combine symptom-focused clinical or population research with strong metabolomics capabilities to discover meaningful and reproducible biomarkers.
What is the larger impact this FOA is aiming for?
The larger goal is to make symptom science more biologically grounded and clinically actionable by identifying metabolic signals that clarify mechanisms, improve measurement, and support better symptom management strategies.
Browse more opportunities from the same category: Education, Health
Next opportunity: Elucidating HIV and HIV-treatment Associated Metabolic/Endocrine Dysfunction (R01)
Previous opportunity: National Fish and Wildlife Foundation
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 030
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 030) also looked into and applied for these:
| Funding Opportunity |
|---|
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21) Apply for RFA CA 16 001 Funding Number: RFA CA 16 001 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R21) Apply for PA 16 029 Funding Number: PA 16 029 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Effects of Drugs of Abuse on Latent HIV Reservoirs in the CNS (R01) Apply for RFA DA 16 014 Funding Number: RFA DA 16 014 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| NCI Research Specialist Award (R50) Apply for PAR 16 025 Funding Number: PAR 16 025 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Drug Discovery For Nervous System Disorders (R01) Apply for PAR 16 041 Funding Number: PAR 16 041 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| HIV/AIDS High Priority Drug Abuse Research (R01) Apply for PAS 16 018 Funding Number: PAS 16 018 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 16 012 Funding Number: RFA DA 16 012 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Genomic Data Analysis Network: Visualization Genomic Data Center (U24) Apply for RFA CA 15 019 Funding Number: RFA CA 15 019 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $660,000 |
| The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) Apply for RFA CA 16 005 Funding Number: RFA CA 16 005 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 16 074 Funding Number: PA 16 074 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $50,000 |
| Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21) Apply for PA 16 075 Funding Number: PA 16 075 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R34) Apply for PA 16 073 Funding Number: PA 16 073 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $225,000 |
| Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01) Apply for PA 16 076 Funding Number: PA 16 076 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $500,000 |
| Behavioral Science Track Award for Rapid Transition (B/Start)(R03) Apply for PAR 16 071 Funding Number: PAR 16 071 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $75,000 |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 16 072 Funding Number: PA 16 072 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 16 084 Funding Number: PAR 16 084 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $275,000 |
| Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Supp) Apply for PA 16 086 Funding Number: PA 16 086 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Imaging and Biomarkers for Early Cancer Detection (U01) Apply for PAR 16 089 Funding Number: PAR 16 089 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization (R44) Apply for RFA CA 16 008 Funding Number: RFA CA 16 008 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01) Apply for PAR 16 105 Funding Number: PAR 16 105 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $400,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 030", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.